Objectives: To determine the short-term clinical effects of levosimendan in acute myocardial infarction (AMI) patients with myocardial stunning after emergency percutaneous coronary intervention (PCI). Methods: The study population consisted of 30 patients with AMI who received emergency PCI and satisfied the inclusion criteria. Levosimendan was given as a continuous infusion of 0.1 μg/kg/min for 24 h, and the remaining 10 patients received placebo treatment. The patients were observed with invasive haemodynamic monitoring and were evaluated biochemically and echocardiographically before and after the drug infusion. Results: Following treatment, biochemical indices (not including creatine kinase and its MB fraction) were significantly lower in the levosimendan group than in the placebo group. Meanwhile, left-ventricular (LV) end-systolic volume, mean pulmonary arterial pressure, pulmonary capillary wedge pressure and systemic vascular resistance were significantly reduced in the levosimendan group, whereas the early-to-late diastolic velocities ratio, LV ejection fraction, cardiac index and cardiac power index were increased. Troponin I levels were reduced and fewer stunned and infarction segments were observed in the patients treated with levosimendan. Conclusions: Levosimendan can significantly improve the myocardium function of patients with myocardial stunning after PCI.

Keywords:
Levosimendan, Myocardial stunning, Percutaneous coronary intervention, Cardiac function
1.
Ganame J, Messalli G, Dymarkowski S, et al: Impact of myocardial haemorrhage on left ventricular function and remodelling in patients with reperfused acute myocardial infarction. Eur Heart J 2009;30:1440-1449.
2.
Luo Y, Cha DG, Liu YL, et al: Coronary microcirculation changes during myocardial stunning in dogs. Cardiology 2010;117:68-74.
3.
Lechner E, Moosbauer W, Pinter M, et al: Use of levosimendan, a new inodilator, for postoperative myocardial stunning in a premature neonate. Pediatr Crit Care Med 2007;8:61-63.
4.
Sonntag S, Sundberg S, Lehtonen LA, et al: The calcium sensitizer levosimendan improves the function of stunned myocardium after percutaneous transluminal coronary angioplasty in acute myocardial ischemia. J Am Coll Cardiol 2004;43:2177-2182.
5.
Meyer K, Klocke RC, Schipke JD, et al: Ca2+ sensitizer superior to catecholamine during myocardial stunning? Eur J Cardiothorac Surg 2008;34:326-331.
6.
Husebye T, Eritsland J, Müller C, et al: Levosimendan in acute heart failure following primary percutaneous coronary intervention-treated acute ST-elevation myocardial infarction. Results from the LEAF trial: a randomized, placebo-controlled study. Eur J Heart Fail 2013;15:565-572.
7.
McMurray JJV, Adamopoulos S, Anker SD, et al: ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012;33:1787-1847.
8.
Steg PG, James SK, Atar D, et al: ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology. Eur Heart J 2012;33:2569-2619.
9.
Bolli R: Why myocardial stunning is clinically important. Basic Res Cardiol 1998;93:169-172.
10.
Bolli R: Mechanism of myocardial ‘stunning'. Circulation 1990;82:723-738.
11.
Bonow RO: Identification of viable myocardium. Circulation 1996;94:2674-2680.
12.
Edes I, Kiss E, Kitada Y, et al: Effects of levosimendan, a cardiotonic agent targeted to troponin C, on cardiac function and on phosphorylation and Ca2+ sensitivity of cardiac myofibrils and sarcoplasmic reticulum in guinea pig heart. Circ Res 1995;77:107-113.
13.
Yokoshiki H, Sperelakis N: Vasodilating mechanisms of levosimendan. Cardiovasc Drugs Ther 2003;17:111-113.
14.
Steffens S, Montecucco F, Mach F: The inflammatory response as a target to reduce myocardial ischaemia and reperfusion injury. Thromb Haemost 2009;102:240-247.
15.
Lilleberg J, Sundberg S, Nieminen MS: Dose-range study of a new calcium sensitizer, levosimendan, in patients with left ventricular dysfunction. J Cardiovasc Pharmacol 1995;26:63-69.
16.
Kerbaul F, Gariboldi V, Giorgi R, et al: Effects of levosimendan on acute pulmonary embolism-induced right ventricular failure. Crit Care Med 2007;35:1948-1954.
17.
Madsen LH, Christensen G, Lund T, et al: Time course of degradation of cardiac troponin I in patients with acute ST-elevation myocardial infarction. The ASSENT-2 troponin substudy. Circ Res 2006;99:1141-1147.
18.
Gao WD, Atar D, Liu Y, et al: Role of troponin I proteolysis in the pathogenesis of stunned myocardium. Circ Res 1997;80:393-399.
19.
Grossini E, Molinari C, Caimmi PP, et al: Levosimendan induces NO production through p38 MAPK, ERK and Akt in porcine coronary endothelial cells: role for mitochondrial KATP channel. Br J Pharmacol 2009;156:250-261.
20.
Caimmi PP, Molinari C, Uberti F, et al: Intracoronary levosimendan prevents myocardial ischemic damages and activates survival signaling through ATP-sensitive potassium channel and nitric oxide. Eur J Cardiothorac Surg 2011;39:e59-e67.
21.
Gruhn N, Nielsen-Kudsk JE, Theilgaard S, et al: Coronary vasorelaxant effect of levosimendan, a new inodilator with calcium-sensitizing properties. J Cardiovasc Pharmacol 1998;31:741-749.
22.
Garlid KD, Dos Santos P, Xie ZJ, et al: Mitochondrial potassium transport: the role of the mitochondrial ATP-sensitive K+ channel in cardiac function and cardioprotection. Biochim Biophys Acta 2003;1606:1-21.
23.
Okorie MI, Bhavsar DD, Ridout D, et al: Postconditioning protects against human endothelial ischaemia-reperfusion injury via subtype-specific KATP channel activation and is mimicked by inhibition of the mitochondrial permeability transition pore. Eur Heart J 2011;32:1266-1274.
24.
Ørn S, Manhenke C, Ueland T, et al: C-reactive protein, infarct size, microvascular obstruction, and left-ventricular remodelling following acute myocardial infarction. Eur Heart J 2009;30:1180-1186.
25.
Mazzone A, Parri M S, Giannessi D, et al: Osteopontin plasma levels and accelerated atherosclerosis in patients with CAD undergoing PCI: a prospective clinical study. Coron Artery Dis 2011;22:179-187.
26.
Jefferies HJ, et al: Frequent hemodialysis schedules are associated with reduced levels of dialysis-induced cardiac injury (myocardial stunning). Clin J Am Soc Nephrol 2011;6:1326-1332.
27.
Steffens S, Montecucco F, Mach F: The inflammatory response as a target to reduce myocardial ischaemia and reperfusion injury. Thromb Haemost 2009;102:240-247.
28.
Anselmi A, Abbate A, Girola F, et al: Myocardial ischemia, stunning, inflammation, and apoptosis during cardiac surgery: a review of evidence. Eur J Cardiothorac Surg 2004;25:304-311.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.